Drug intelligence / Profile preview

ATLX-2199

Development stage: Preclinical
Lead developer: Alchemab Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ATLX-2199 is an experimental monoclonal antibody being developed by Alchemab Therapeutics for the treatment of muscle atrophy and Parkinson's disease. The drug candidate was discovered using Alchemab's proprietary platform, which identifies naturally occurring, protective antibodies from 'resilient' individuals—those who remain healthy despite a high risk of developing specific diseases. By mimicking these protective immune responses, ATLX-2199 aims to provide a therapeutic benefit in neurodegenerative and muscle-wasting conditions. As of early 2024, the specific molecular target of ATLX-2199 remains undisclosed by the company.

Beyond the preview

Go deeper on ATLX-2199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLX-2199.

Explore the full profile